Company
Headquarters: Velizy-Villacoublay, France
Employees: 139
CEO: Mr. Stephane Piat
€168.5 Million
EUR as of Jan. 1, 2024
US$186.1 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in Vélizy-Villacoublay, France.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Carmat SA has the following listings and related stock indices.
Stock: Euronext: ALCAR wb_incandescent
Stock: FSX: CXT wb_incandescent